Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review4832 has been discontinued.
View all Glutamate (Metabotropic) Group III Receptors products.AZ 12216052 is a positive allosteric modulator at mGlu8 receptors. Exhibits anxiolytic effects in mouse models of anxiety.
分子量 | 392.35 |
公式 | C19H22BrNOS |
储存 | Store at -20°C |
纯度 | ≥97% (HPLC) |
CAS Number | 1290628-31-7 |
PubChem ID | 73755190 |
InChI Key | QKUYZJOTWYRWNF-UHFFFAOYSA-N |
Smiles | BrC1=CC=C(CSCC(NC2=CC=C(C(C)CC)C=C2)=O)C=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Chruscicka et al (2013) Expression of metabotropic glutamate receptors in mammalian cells as a method for identification of new chemical compounds with drug-like activity. Pharmacol.Rep. 65 38
Duvoisin et al (2011) Opposing roles of mGluR8 in measures of anxiety involving non-social and social challenges. Behav.Brain Res. 221 50 PMID: 21382421
Duvoisin et al (2010) Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav.Brain Res. 212 168 PMID: 20385173
关键词: AZ 12216052, AZ 12216052 supplier, AZ12216052, anxiolytics, mGluR8, positive, allosteric, modulators, PAMs, Glutamate, (Metabotropic), Group, III, Receptors, 4832, Tocris Bioscience
目前没有该产品的评论。 Be the first to review AZ 12216052 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.